Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant anti-VEGF humanized monoclonal antibody vs Avastin in non-squamous NSCLC
CTR20190071Phase 3Completed
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant anti-VEGF humanized monoclonal antibody in non-small cell lung cancer (NSCLC), sponsored by Jiangsu Aosaikang Pharmaceutical Co., Ltd.. Started Apr 2019; status: completed.
02
Drugs
recombinant anti-VEGF humanized monoclonal antibody
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20190071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190071.